Genetics help solve eye cancer mystery

Article

It is now possible, for the first time, to biopsy tissue from a living eye in order to determine which tumours possess high metastatic risk, according to a report in the November 2006 issue of Ophthalmology.

It is now possible, for the first time, to biopsy tissue from a living eye in order to determine which tumours possess high metastatic risk, according to a report in the November 2006 issue of Ophthalmology.

Researchers from the University of California, Los Angeles, Jules Stein Eye Institute, USA, have pioneered a technique that allows them to identify which tumours are the most aggressive and are likely to spread. Ocular melanoma attacks the pigment cells in the retina and previous studies discovered that subjects who are missing one copy of chromosome 3 in their tumour tissue are more likely to have highly aggressive cancers.

The UCLA researchers, using this genetic marker, studied a group of nine patients, newly diagnosed with ocular melanoma. Each patient underwent surgery to implant a small disc designed to shrink the tumour and, during surgery, surgeons used an ultra-fine needle to collect cells from the tumour and send them to the laboratory for culture. After growing the cells, a geneticist analysed them to determine whether they were missing the essential gene. Of the nine patients, four were identified as being high risk and five as being low risk.

The authors believe that this new technique will not only provide a greater medical understanding of each case but will also go some way to help alleviate the patients psychological trauma of not knowing what kind of cancer they have and whether it is likely to be life-threatening or not.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.